The Conversation (0)
Krystal Biotech announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.
Krystal Biotech (NASDAQ:KRYS)Â announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.
As quoted in the press release:
KB103 is Krystal’s lead product candidate, currently in preclinical development and seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin. KB103 is a replication-defective, non-integrating viral vector that has been engineered employing Krystal’s STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells.
Click here to read the full press release.
Source: globenewswire.com